Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 70Thoracic 3Sarcoma 2Gynecologic 2Other solid neoplasm 1

Conditions

Platinum Resistant Ovarian Cancer 1Endometrial Neoplasms 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 134pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Letrozole 28Drug Therapy 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23durvalumab 22Albumin-Bound Paclitaxel 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20Specimen Handling 20Filgrastim 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × HMPL-013 × Gynecologic × Clear all
NCT07170982 2025-09-12

Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer

Sun Yat-sen University

Phase 2 Not yet recruiting
128 enrolled
Gynecologic

Endometrial Neoplasms

NCT06973421 2025-05-15

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

Fudan University

Phase 2 Not yet recruiting
35 enrolled
Gynecologic

Platinum Resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡